Transformation in Trials
Rob Freistat, President of Uncommon Cures, discusses how clinical trials are transforming to accelerate drug development and ensure patients receive treatments faster, particularly in the rare disease space.
Feels Like Home: Designing Sites For Patient Comfort
Originally published on Clinical Leader By Rob Freishtat, MD, MPH, president and co-founder, Uncommon Cures, and Matthew Stares, senior vice president, global real estate, architecture and development, MillerKnoll More than half (55%) of clinical trial failures are a result of enrollment issues, according to GlobalData. Those issues are myriad, but, commonly, many patients feel overwhelmed by […]
Feels Like Home: Designing Sites For Patient Comfort
By Rob Freishtat, MD, MPH, president and co-founder, Uncommon Cures, and Matthew Stares, senior vice president, global real estate, architecture and development, MillerKnoll More than half (55%) of clinical trial failures are a result of enrollment issues, according to GlobalData. Those issues are myriad, but, commonly, many patients feel overwhelmed by the prospect of participating in […]
Improving The Clinical Trial Ecosystem: A Call To Stakeholder Alignment
We live in an era of extraordinary scientific advancement, and as a result, we are seeing rapid growth in the development of new drugs. When the clinical trial ecosystem works, we deliver on our promise as an industry to help patients — especially those with rare and complex diseases. But when the ecosystem grinds to […]
Uncommon Curess, LLC Is Please To Announce That Dr. Tam Roshan Lal Has Joined The Company As Chief Medical Officer.
For Immediate Release Uncommon Cures, LLC is pleased to announce that Dr. Tam Roshan Lal has joined the company as Chief Medical Officer. Dr. Roshan Lal is an experienced rare disease clinician with extensive clinical trials experience. Prior to joining Uncommon Cure, she worked as an Attending Metabolic Geneticist at the Rare Disease Institute (RDI), Childrens National […]